Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3478-3483

  Cascinu, Stefano ^a   Catalano, Vincenzo ^a   Cordella, Luigi ^a   Labianca, Roberto ^a   Giordani, Paolo ^a   Baldelli, Anna Maria ^a   Beretta, Giordano D ^a   Ubiali, Emilio ^a   Catalano, Giuseppina ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; OXALIPLATIN; PLACEBO; SODIUM CHLORIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROPATHY; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NERVE CONDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 0037102328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.061     Document Type: Article

References (23)

1. Oxaliplatin clinical activity: A review
2. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
3. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
4. Oxaliplatin added to 5-fluorouracil-based therapy in the treatment of 5FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program
5. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
6. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
7. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced epithelial ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
8. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
9. Oxaliplatin: A review of its pharmacological properties and clinical, efficacy in metastatic colorectal cancer and its potential in other malignancies
10. Pharmacokinetics and safety profile of oxaliplatin
11. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats
12. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues and morphologic evidence of toxicity
13. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model
14. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats
15. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin
16. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A double-blind placebo-controlled trial
17. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial
18. Neuropathy following ormaplatin administration: Human and laboratory studies
19. Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of FAS/FAS ligand
20. Oxaliplatin induced neuropathy: Could gabapentin be the answer?